{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-125413","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.581526+00:00","generated_at":"2026-05-16T12:15:10.938315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025","bullets":["Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.","R&D expenses $9.2M vs $11.9M YoY; G&A $18.5M vs $18.2M YoY.","Raised ~$61M in gross proceeds: $25M at Citius Pharma, $36M at Citius Oncology (CTOR).","LYMPHIR launched in U.S. December 2025 for CTCL; secured NCCN Category 2A and HCPCS J-code.","Cash and equivalents $4.3M at Sep 30, 2025; continued FDA engagement on Mino-Lok and Halo-Lido."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-125413","json":"https://secwatch.observer/filing/0001213900-25-125413.json","markdown":"https://secwatch.observer/filing/0001213900-25-125413.md","text":"https://secwatch.observer/filing/0001213900-25-125413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/0001213900-25-125413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/ea0270776-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:15:10.938315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}